Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00712556 · ClinicalTrials.gov registry record
PET Study in Patients With Non-Hodgkin Lymphoma
A clinical trial, sponsored by Vanderbilt-Ingram Cancer Center.
- Completed
- Registry status
- 55
- Enrollment target
NCT00712556: Completed study, sponsored by Vanderbilt-Ingram Cancer Center.
NCT00712556 is a clinical trial that has completed, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 55 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00712556 has completed, sponsored by Vanderbilt-Ingram Cancer Center.
- COMPLETED
- Registry status
- 55 participants
- Enrollment target
Study Summary
RATIONALE: Diagnostic procedures, such as fluorine 18-fludeoxyglucose positron emission tomography (PET) scans, may help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This phase I trial is studying fluorine 18-fludeoxyglucose PET scan to see how well it predicts outcomes in patients who have undergone high-dose chemotherapy and autologous stem cell transplant for non-Hodgkin lymphoma.
Interventions
- RADIATION fluorine 18-fludeoxyglucose positron emission tomography
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2008-05 |
| Est. Completion | 2009-03 |
What the finished NCT00712556 record still lists
NCT00712556 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 55 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which fluorine 18-fludeoxyglucose positron emission tomography is the first listed.
NCT00712556 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00712556 about?
NCT00712556 is a clinical study titled "PET Study in Patients With Non-Hodgkin Lymphoma". RATIONALE: Diagnostic procedures, such as fluorine 18-fludeoxyglucose positron emission tomography (PET) scans, may help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This phase I trial is studying fluorine 18-fludeoxyglucose PET scan to see how well i...
What is the current status of trial NCT00712556?
This trial is currently completed. The enrollment target is 55 participants. The study started on 2008-05. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00712556?
The interventions under investigation include: fluorine 18-fludeoxyglucose positron emission tomography (RADIATION).
Who is sponsoring clinical trial NCT00712556?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia